SG233

SG233 is a preclinical-stage in vivo cell engineering candidate developed by Sana Biotechnology. It utilizes the company's proprietary fusogen technology to target CD8+ T cells and deliver a genetic payload encoding chimeric antigen receptors (CARs) directed against CD19 and CD22. By facilitating the production of CAR T cells directly within the patient's body, SG233 aims to treat B-cell malignancies while bypassing the logistical and manufacturing challenges associated with traditional ex vivo CAR T therapies, such as the need for lymphodepletion and specialized cell processing facilities. The program is part of Sana's broader in vivo cell engineering platform, which leverages engineered viral vectors or virus-like particles to modify specific cell types in situ.